Stocks
bluebird bio, Inc.BLUE
NASDAQHealthcareBiotechnology$4.97+0.00%
Focused on developing gene therapies for severe genetic diseases and cancer, this biotech firm has faced significant volatility due to the high-risk nature of its clinical pipeline. Investors monitor its progress in securing FDA approvals and commercializing treatments like Zynteglo for beta-thalassemia.
Market Cap: $48.7M52W Range: $3.20 – $28.60
Congressional Interest in bluebird bio, Inc. (BLUE)
1 member of Congress has disclosed 4 trades in bluebird bio, Inc. (BLUE), a Healthcare company. The buy/sell breakdown shows 2 purchases versus 2 sales. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
4
Unique Politicians
1
Buys
2
Sells
2
Who in Congress Is Trading BLUE?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2020-12-11 | Lois Frankel | sell | $1K – $15K |
| 2020-12-10 | Lois Frankel | sell | $1K – $15K |
| 2020-07-15 | Lois Frankel | buy | $1K – $15K |
| 2020-04-27 | Lois Frankel | buy | $1K – $15K |